Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.33 |
| ▸ | TET3 | O43151 | 3/20 | 0.33 |
| ▸ | FBXL19 | Q6PCT2 | 3/20 | 0.33 |
| ▸ | CXXC5 | Q7LFL8 | 3/20 | 0.33 |
| ▸ | TET1 | Q8NFU7 | 3/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.33 |
| ▸ | CXXC4 | Q9H2H0 | 3/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328751 | 0.78 | TEAD1 (0.45) | TEAD1TEAD3 | |
| SCHEMBL24668287 | 0.74 | TEAD3 (0.36) | TEAD1TEAD3KMT2ATET3FBXL19 | |
| SCHEMBL23328992 | 0.73 | JAK3 (0.37) | TEAD1TEAD3 | |
| SCHEMBL8554497 | 0.73 | TEAD3 (0.35) | TEAD1TEAD3KMT2ATET3FBXL19 | |
| SCHEMBL23328270 | 0.72 | TEAD3 (0.47) | TEAD3KMT2AMEN1 | |
| SCHEMBL28328148 | 0.71 | KMT2A (0.35) | TEAD1TEAD3KMT2ATET3FBXL19 | |
| SCHEMBL23328327 | 0.70 | TEAD3 (0.41) | TEAD1TEAD3KMT2ATET3FBXL19 | |
| SCHEMBL23328272 | 0.70 | TEAD1 (0.49) | TEAD1TEAD3 | |
| SCHEMBL20547259 | 0.70 | TET3 (0.47) | TEAD1TEAD3KMT2ATET3FBXL19 | |
| SCHEMBL237862 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | TEAD1 1181/4885TEAD3 1649/4885KMT2A 3253/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | TEAD1 1176/4885TEAD3 1580/4885KMT2A 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.